Nextech Invest is a Zurich, Switzerland-based venture capital firm. Value Add VC tracks 5 companies Nextech Invest has invested in and 2 venture rounds it took part in (1 as lead).
Nextech Invest key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Headquarters | Zurich, Switzerland | SEC Form ADV (IAPD), September 16, 2026 |
| Type | Venture capital firm | Value Add VC classification |
| Partners and team | Melissa McCracken, Ph.D. (Partner); Rocco Sgobbo (Managing Partner, COO); Thilo Schroeder, Ph.D. (Managing Partner); Kanishka Pothula (Managing Partner) | nextechinvest.com, October 24, 2026 |
| Notable investments | ORIC Pharmaceuticals | nextechinvest.com, October 24, 2026 |
| Venture rounds tracked | 2 (led 1, joined 1) 2 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 5 | Portfolio list on this page |
Nextech Invest overview
Nextech Invest is a Zurich-based investor in emerging biotechnology companies developing cancer medicines and precision medicine.[1] The firm says it supports portfolio companies through critical moments of scientific and clinical validation.[2] Its team includes managing partners Thilo Schroeder, Kanishka Pothula and Rocco Sgobbo, with biotech entrepreneur Alexis Borisy as chairman.[3] Portfolio companies the firm lists as exited include Mirati Therapeutics, Blueprint Medicines, Peloton Therapeutics and Vividion Therapeutics.[2]
Recent deals we track
2Track record: led 1 and participated in 1 of 2 tracked venture rounds · 2 in the last 12 months · led 1 Series C
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | Khartis Therapeutics | Series B | Participated | $50M | — | Foresite CapitalunverifiedLilly Asia VenturesunverifiedNextech InvestunverifiedForge Life Science Partners | Pulse story |
| Jun 30, 2026 | Flare Therapeutics | Series C | Led | $85M | — | Pulse story |
Is something wrong on this page?
About Nextech Invest
Its partners and team include Melissa McCracken, Ph.D. (Partner), Rocco Sgobbo (Managing Partner, COO), Thilo Schroeder, Ph.D. (Managing Partner) and Kanishka Pothula (Managing Partner).[nextechinvest.com] Its investments include ORIC Pharmaceuticals (multiple rounds).[nextechinvest.com]
Nextech Invest partners and team
4- Melissa McCracken, Ph.D. · Partner (nextechinvest.com)
- Rocco Sgobbo · Managing Partner, COO (nextechinvest.com)
- Thilo Schroeder, Ph.D. · Managing Partner (nextechinvest.com)
- Kanishka Pothula · Managing Partner (nextechinvest.com)
Notable Nextech Invest investments
1- ORIC Pharmaceuticals · multiple rounds (nextechinvest.com, October 24, 2026)
At a glance
Nextech Invest appears in 2 funding rounds tracked by ValueAddVC since 2026, leading 1. Its most recent tracked deal was Khartis Therapeutics' $50M Series B round (Aug 13, 2026).
Strategy
Recent changes
- Aug 13, 2026Aug 13, 2026Invested in Khartis Therapeutics (Series B, $50M) Axios
- Jun 30, 2026Jun 30, 2026Invested in Flare Therapeutics (Series C, $85M) GlobeNewswire
Portfolio
5 totalSector / Stage Activity
Co-Investors
11Similar Firms
overlapping sector, stage or regionLatest Pulse
- Aug 13, 2026Khartis Emerges From Stealth With $95M for a Thyroid PillKhartis Therapeutics emerged from stealth with $95 million in total funding, including a new $50 million Series B, to develop an oral alternative to injectable treatments for thyroid eye disease.→
- Jul 2, 2026Crunchbase: The Week's 10 Biggest Funding Rounds, Led by Joulent's $1.75B Energy RaiseCrunchbase News' roundup of the week's 10 biggest funding rounds (June 27-July 2) was led by Houston-based energy infrastructure provider Joulent's $1.75 billion raise from National Grid Ventures, aimed squarely at AI and compute-intensive industries' power needs. Together AI's $800M Series C and Venice AI's $65M unicorn round both placed inside the top 10, alongside biotech, legal-tech, sports and video-AI rounds spanning a genuinely broad set of categories beyond pure frontier-model AI.→
- Jun 30, 2026Flare Therapeutics Raises $85M, Names New CEOFlare Therapeutics closed an $85 million insider-led Series C and named Anna Protopapas CEO, funding its first-in-class ARON-targeting degrader for prostate cancer toward a Phase 1A trial expected in Q3 2026.→
Nextech Invest FAQ
What stage does Nextech Invest invest at?
In the rounds Value Add VC tracks, Nextech Invest's deals were most often Series B (1) and Series C (1); it led 1 Series C.
Who are the partners at Nextech Invest?
Nextech Invest's partners and team include Melissa McCracken, Ph.D. (Partner), Rocco Sgobbo (Managing Partner, COO), Thilo Schroeder, Ph.D. (Managing Partner) and Kanishka Pothula (Managing Partner), according to nextechinvest.com.
What companies has Nextech Invest backed?
Notable Nextech Invest investments include ORIC Pharmaceuticals (multiple rounds), according to nextechinvest.com. Companies Value Add VC tracks as Nextech Invest investments include Silence Therapeutics, Khartis Therapeutics, Attovia Therapeutics, Flare Therapeutics and Parabilis Medicines.
Where is Nextech Invest based?
Nextech Invest is headquartered in Zurich, Switzerland, according to SEC Form ADV (IAPD).
Who does Nextech Invest co-invest with most?
In the rounds Value Add tracks, Nextech Invest most often invests alongside ARCH Venture Partners (1 shared deal), Casdin Capital (1 shared deal), Deep Track Capital (1 shared deal), Eli Lilly (1 shared deal), Eli Lilly and Company (1 shared deal).
References
researched 2026-10-24Sources & methodologyshow
- GlobeNewswireprimary source1 fact
- Axiosmajor outlet1 fact
- nextechinvest.comValue Add VC data4 facts
- nextechinvest.comValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.